Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Breast 2Head & Neck 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Transitional Cell 12Urinary Bladder Neoplasms 9Ureteral Neoplasms 4Urologic Neoplasms 3Urethral Neoplasms 2Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Urothelial Cancer 1Urologic Diseases 1Urogenital Neoplasms 1Urogenital Diseases 1Urinary Bladder Diseases 1Triple Negative Breast Neoplasms 1Salivary Gland Neoplasms 1Peripheral Nervous System Diseases 1Penile Squamous Cell Carcinoma (PSCC) 1Neoplasms by Site 1Neoplasms 1Muscle-invasive Bladder Cancer 1Muscle Invasive Bladder Urothelial Carcinoma 1Metastatic Urothelial Cancer 1Male Urogenital Diseases 1Head and Neck Neoplasms 1Female Urogenital Diseases 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Carcinoma, Adenoid Cystic 1Adenocarcinoma of the Bladder 1

Interventions

pembrolizumab 128Carboplatin 126Pemetrexed 106Cisplatin 79Paclitaxel 60osimertinib 54Nivolumab 53Docetaxel 52durvalumab 48Specimen Handling 40Magnetic Resonance Spectroscopy 36Gemcitabine 36Radiosurgery 29atezolizumab 27130-nm albumin-bound paclitaxel 27Cetuximab 26Radiotherapy 23Ipilimumab 22Drug Therapy 22cemiplimab 20Bevacizumab 20amivantamab 18Taxes 16Ramucirumab 13tislelizumab 12alectinib 12Radiation 12Biopsy 12lazertinib 11Oxaliplatin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × enfortumab vedotin × 90 days × Clear all
NCT07287995 2026-04-23

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

Astellas Pharma Inc

Phase 1/2 Recruiting
428 enrolled
BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT04225117 2026-04-13

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Astellas Pharma Inc

Phase 2 Active not recruiting
329 enrolled 23 charts
BreastGastrointestinalHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡